Vitamins MK4 and MK7, forms of Vitamin K2, play a role in blood coagulation by supporting the activation of clotting factors in the liver. They help produce functional proteins like factors II (thrombin), VII, IX, and X, which are essential for the clotting cascade. However, their effects on coagulation are generally regulatory and not excessive in healthy individuals with normal vitamin K levels.
MK4: Rapidly absorbed, shorter half-life (less than 24 hours). It supports clotting factor activation but is less studied for coagulation impact compared to MK7.
MK7: Longer half-life (3 days), more stable in blood. Studies suggest it may slightly enhance coagulation in vitamin K-deficient individuals but doesn’t significantly increase clotting risk in healthy people.
In vitamin K deficiency, MK4 or MK7 supplementation can normalize coagulation, potentially increasing clotting compared to a deficient state. In healthy individuals, therapeutic doses (e.g., 45–200 mcg/day MK7) typically don’t cause hypercoagulation, as vitamin K’s role is tightly regulated.
High doses (e.g., >1 mg/day) or use with anticoagulants (like warfarin, which MK4 and MK7 can counteract) may increase clotting risk, requiring medical supervision.
People on anticoagulants should avoid MK4/MK7 supplements unless advised by a doctor, as they can interfere with therapy.
No strong evidence suggests MK4 or MK7 causes excessive clotting in healthy individuals at standard doses.
No comments:
Post a Comment